Wicher G, Roy A, Vaccaro A, Vemuri K, Ramachandran M, Olofsson T
Neurooncol Adv. 2025; 7(1):vdaf010.
PMID: 39931535
PMC: 11808570.
DOI: 10.1093/noajnl/vdaf010.
Chen Z, Liu C, Zheng W, Li Z, Tang Y, Peng J
Sci Rep. 2025; 15(1):4618.
PMID: 39920245
PMC: 11806050.
DOI: 10.1038/s41598-025-87151-z.
Ni H, Reitman Z, Zou W, Akhtar M, Paul R, Huang M
Nat Cancer. 2025; .
PMID: 39910249
DOI: 10.1038/s43018-025-00905-6.
Jackson L, Erickson A, Camphausen K, Krauze A
Curr Oncol. 2025; 32(1).
PMID: 39851932
PMC: 11763554.
DOI: 10.3390/curroncol32010016.
Kim S, Kim K, Jung H, Jeong E, Lee H, Kwon J
J Cancer. 2025; 16(3):802-811.
PMID: 39781345
PMC: 11705068.
DOI: 10.7150/jca.104759.
Acetylation of E2F1 at K125 facilitates cell apoptosis under serum stress.
Fang Z, Gong C, Hu Y, Cui T, Lin M, Lin S
Transl Oncol. 2024; 52():102259.
PMID: 39731810
PMC: 11743828.
DOI: 10.1016/j.tranon.2024.102259.
ALDH1L2 drives HCC progression through TAM polarization.
Li J, Zhang C, Zhou Q, Long Q, Chen J, Meng L
JHEP Rep. 2024; 7(1):101217.
PMID: 39687603
PMC: 11648791.
DOI: 10.1016/j.jhepr.2024.101217.
Exosome-derived circ-001422 promotes tumor-associated macrophage M2 polarization to accelerate the progression of glioma.
Cao W, Zeng Z, Sun J, Chen Y, Kuang F, Luo S
Commun Biol. 2024; 7(1):1504.
PMID: 39538012
PMC: 11561164.
DOI: 10.1038/s42003-024-07134-0.
Markers of tumor-associated macrophages and microglia exhibit high intratumoral heterogeneity in human glioblastoma tissue.
Ispirjan M, Marx S, Freund E, Fleck S, Baldauf J, Roessler K
Oncoimmunology. 2024; 13(1):2425124.
PMID: 39523551
PMC: 11556281.
DOI: 10.1080/2162402X.2024.2425124.
Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity.
Brem S
Brain Behav Immun Health. 2024; 42:100859.
PMID: 39512605
PMC: 11541944.
DOI: 10.1016/j.bbih.2024.100859.
Chimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.
Gallus M, Young J, Cook Quackenbush S, Khasraw M, de Groot J, Okada H
Neuro Oncol. 2024; 27(2):352-368.
PMID: 39450490
PMC: 11812040.
DOI: 10.1093/neuonc/noae203.
The MCIB Model: A Novel Theory for Describing the Spatial Heterogeneity of the Tumor Microenvironment.
Guo M, Sun Y, Wang X, Wang Z, Yuan X, Chen X
Int J Mol Sci. 2024; 25(19).
PMID: 39408814
PMC: 11476373.
DOI: 10.3390/ijms251910486.
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials.
Tapescu I, Madsen P, Lowenstein P, Castro M, Bagley S, Fan Y
Front Oncol. 2024; 14:1454370.
PMID: 39399167
PMC: 11466887.
DOI: 10.3389/fonc.2024.1454370.
Immunoediting Dynamics in Glioblastoma: Implications for Immunotherapy Approaches.
Amin T, Hossain A, Jerin N, Mahmud I, Rahman M, Islam S
Cancer Control. 2024; 31:10732748241290067.
PMID: 39353594
PMC: 11459535.
DOI: 10.1177/10732748241290067.
Immunomodulatory Therapy for Ischemic Heart Disease.
Zhao X, Williamson T, Gong Y, Epstein J, Fan Y
Circulation. 2024; 150(13):1050-1058.
PMID: 39325497
PMC: 11521113.
DOI: 10.1161/CIRCULATIONAHA.124.070368.
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy.
Chen F, Xue Y, Zhang W, Zhou H, Zhou Z, Chen T
Cancer Metastasis Rev. 2024; 43(4):1419-1443.
PMID: 39307891
PMC: 11554835.
DOI: 10.1007/s10555-024-10211-9.
Key Cell-in-Cell Related Genes are Identified by Bioinformatics and Experiments in Glioblastoma.
Zhang F, Ye J, Zhu J, Qian W, Wang H, Luo C
Cancer Manag Res. 2024; 16:1109-1130.
PMID: 39253064
PMC: 11382672.
DOI: 10.2147/CMAR.S475513.
Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.
Fei X, Wu J, Tian H, Jiang D, Chen H, Yan K
Cancer Biomark. 2024; 41(1):1-24.
PMID: 39240627
PMC: 11492047.
DOI: 10.3233/CBM-230486.
Interleukin 6 and cancer resistance in glioblastoma multiforme.
Detchou D, Barrie U
Neurosurg Rev. 2024; 47(1):541.
PMID: 39231832
DOI: 10.1007/s10143-024-02783-5.
Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
Feldman L
Front Immunol. 2024; 15:1384249.
PMID: 38994360
PMC: 11238147.
DOI: 10.3389/fimmu.2024.1384249.